Sofinnova Investments, Inc. — 13F Holdings & Portfolio
CIK 1631134 · latest 13F-HR filed 2026-08-14
Sofinnova Investments, Inc. manages $1.93B in 13F-reported U.S. long-equity assets across 57 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are NTRA (21.76%), VERA (6.20%), GMAB (5.74%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 11 new positions and exited 19; 24 existing positions rose in reported value and 14 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 59.8%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 27, 2026.
3-150
MENLO PARK, CA 94025
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| AUBER, NATHALIE, MARIE Control | PARTNER AND CHIEF FINANCIAL OFFICER since Jan 1998 | 5–10% | Individual |
| AZAN, ALAIN, LOUIS Control | SHAREHOLDER since Jun 1997 | 5–10% | Individual |
| BRODY, JAMES, DENNIS Control | CHIEF COMPLIANCE OFFICER since Oct 2016 | Less than 5% | Individual |
| DELBRIDGE, ERIC, HELMUT Control | GENERAL PARTNER, PUBLIC EQUITY since May 2016 | Less than 5% | Individual |
| EKMAN, LARS, GOSTA Control | EXECUTIVE PARTNER, PRIVATE EQUITY since Sep 2016 | Less than 5% | Individual |
| HEALY, JAMES, IRVIN Control | MANAGING PARTNER since Jun 2000 | 50–75% | Individual |
| KATABI, MAHA, MEHDI Control | GENERAL PARTNER since Apr 2019 | 10–25% | Individual |
| SHAHLAVI, HOOMAN, NO MIDDLE NAME Control | PARTNER AND CHIEF LEGAL OFFICER since Feb 2007 | 5–10% | Individual |
Ownership & leadership changes · 13 filings with changes since Mar 30, 2012
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- ChangedAUBER, NATHALIE, MARIE · title SHAREHOLDER, DIRECTOR AND CHIEF FINANCIAL OFFICER → PARTNER AND CHIEF FINANCIAL OFFICER
- ChangedDELBRIDGE, ERIC, HELMUT · title DIRECTOR → GENERAL PARTNER, PUBLIC EQUITY
- ChangedEKMAN, LARS, GOSTA · title BOARD OF DIRECTORS MEMBER, EXECUTIVE PARTNER → EXECUTIVE PARTNER, PRIVATE EQUITY
- ChangedHEALY, JAMES, IRVIN · title SHAREHOLDER, DIRECTOR → MANAGING PARTNER
- ChangedKATABI, MAHA, MEHDI · title SHAREHOLDER, DIRECTOR AND VICE PRESIDENT → GENERAL PARTNER
- ChangedSHAHLAVI, HOOMAN, NO MIDDLE NAME · title SHAREHOLDER, SECRETARY AND CHIEF LEGAL OFFICER → PARTNER AND CHIEF LEGAL OFFICER
- AddedDELBRIDGE, ERIC, HELMUT · DIRECTOR · Less than 5% · control person
- ChangedHEALY, JAMES, IRVIN · title SHAREHOLDER, DIRECTOR AND PRESIDENT → SHAREHOLDER, DIRECTOR
- ChangedSHAHLAVI, HOOMAN, NO MIDDLE NAME · now a control person
- AddedEKMAN, LARS, GOSTA · BOARD OF DIRECTORS MEMBER, EXECUTIVE PARTNER · Less than 5% · control person
- No longer listedBHAGAT, SARAH, MANECK · SHAREHOLDER AND DIRECTOR · 10–25% · control person · listed since May 2017
- No longer listedPOWELL, MICHAEL, FRANK · SHAREHOLDER, DIRECTOR AND VICE PRESIDENT · 10–25% · control person · listed since Aug 1997
- ChangedAUBER, NATHALIE, MARIE · ownership 10–25% → 5–10%
- ChangedAZAN, ALAIN, LOUIS · ownership 10–25% → 5–10%
- ChangedBHAGAT, SARAH, MANECK · ownership 5–10% → 10–25%
- ChangedHEALY, JAMES, IRVIN · ownership 10–25% → 50–75%
- ChangedKATABI, MAHA, MEHDI · ownership 5–10% → 10–25%
- AddedBHAGAT, SARAH, MANECK · SHAREHOLDER AND DIRECTOR · 5–10% · control person
- AddedKATABI, MAHA, MEHDI · SHAREHOLDER, DIRECTOR AND VICE PRESIDENT · 5–10% · control person
- No longer listedMEHRA, ANAND, NO MIDDLE NAME · SHAREHOLDER · 10–25% · control person · listed since May 2007
- ChangedSHAHLAVI, HOOMAN, NO MIDDLE NAME · title SHAREHOLDER, SECRETARY AND GENERAL COUNSEL → SHAREHOLDER, SECRETARY AND CHIEF LEGAL OFFICER
- ChangedMEHRA, ANAND, NO MIDDLE NAME · title SHAREHOLDER, DIRECTOR AND VICE PRESIDENT → SHAREHOLDER
- ChangedAZAN, ALAIN, LOUIS · title SHAREHOLDER AND DIRECTOR → SHAREHOLDER
Older changes (4 more filings)
- AddedBRODY, JAMES, DENNIS · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- AddedMEHRA, ANAND, NO MIDDLE NAME · SHAREHOLDER, DIRECTOR AND VICE PRESIDENT · 10–25% · control person
- ChangedAUBER, NATHALIE, MARIE · ownership Less than 5% → 10–25%
- ChangedSHAHLAVI, HOOMAN, NO MIDDLE NAME · title SECRETARY AND GENERAL COUNSEL → SHAREHOLDER, SECRETARY AND GENERAL COUNSEL; ownership Less than 5% → 5–10%
- No longer listedAKKARAJU, SRINIVAS · SHAREHOLDER, DIRECTOR AND VICE PRESIDENT · 10–25% · control person · listed since Jun 2013
- No longer listedBUATOIS, ERIC, PIERRE · SHAREHOLDER AND VICE PRESIDENT · 10–25% · control person · listed since Aug 2001
- No longer listedKONG, GARHENG, ALBERT · SHAREHOLDER, DIRECTOR AND VICE PRESIDENT · 10–25% · control person · listed since Sep 2010
- AddedAKKARAJU, SRINIVAS · SHAREHOLDER, DIRECTOR AND VICE PRESIDENT · 10–25% · control person
- ListedAUBER, NATHALIE, MARIE · SHAREHOLDER, DIRECTOR AND CHIEF FINANCIAL OFFICER · Less than 5% · control person
- ListedAZAN, ALAIN, LOUIS · SHAREHOLDER AND DIRECTOR · 10–25% · control person
- ListedBUATOIS, ERIC, PIERRE · SHAREHOLDER AND VICE PRESIDENT · 10–25% · control person
- ListedHEALY, JAMES, IRVIN · SHAREHOLDER, DIRECTOR AND PRESIDENT · 10–25% · control person
- ListedKONG, GARHENG, ALBERT · SHAREHOLDER, DIRECTOR AND VICE PRESIDENT · 10–25% · control person
- ListedPOWELL, MICHAEL, FRANK · SHAREHOLDER, DIRECTOR AND VICE PRESIDENT · 10–25% · control person
- ListedSHAHLAVI, HOOMAN, NO MIDDLE NAME · SECRETARY AND GENERAL COUNSEL · Less than 5%
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- Natera Inc$110.8M +35.7%
- Genmab A/S$90.9M +450.6%
- Arrivent BioPharma Inc$19.8M +50.6%
- Rapport Therapeutics Inc$19.8M +33.2%
- Anaptysbio Inc$19.5M +142.0%
Top Trims
- Bristol-Myers Squibb Co-$70.1M -58.1%
- United Therapeutics Corp Del-$53.5M -56.3%
- Cogent Biosciences Inc-$41.3M -50.8%
- Insmed Inc-$39.7M -70.2%
- Alcon AG-$37.8M -68.8%
New Positions
- Seaport Therapeutics Inc$77.4M
- Gilead Sciences Inc$43.3M
- Nurix Therapeutics Inc$12.7M
- Design Therapeutics Inc$12.5M
- First Tracks Biotherapeutics$11.4M
Exited Positions
- AstraZeneca PLC$89.9M
- Biogen Inc$42.1M
- Celcuity Inc$41.8M
- BridgeBio Pharma Inc$30.4M
- Dexcom Inc$24.7M
Sofinnova Investments, Inc. Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Natera Inc | NTRA | 632307104 | $420.8M | 21.76% | 1,550,280 | SH |
| 2 | Vera Therapeutics Inc | VERA | 92337R101 | $119.9M | 6.20% | 2,793,987 | SH |
| 3 | Genmab A/S | GMAB | 372303206 | $111.1M | 5.74% | 4,045,215 | SH |
| 4 | Jazz Pharmaceuticals PLC | JAZZ | G50871105 | $88.0M | 4.55% | 365,341 | SH |
| 5 | Rapport Therapeutics Inc | RAPP | 75383L102 | $79.4M | 4.10% | 1,904,408 | SH |
| 6 | Seaport Therapeutics Inc | SPTX | 81221K108 | $77.4M | 4.00% | 3,564,871 | SH |
| 7 | Arrivent BioPharma Inc | AVBP | 04272N102 | $58.9M | 3.05% | 1,696,752 | SH |
| 8 | Ultragenyx Pharmaceutical In | RARE | 90400D108 | $57.3M | 2.96% | 1,717,505 | SH |
| 9 | BioAge Labs Inc | BIOA | 09077V100 | $56.2M | 2.91% | 2,293,788 | SH |
| 10 | Bristol-Myers Squibb Co | BMY | 110122108 | $50.5M | 2.61% | 876,970 | SH |
| 11 | Supernus Pharmaceuticals | SUPN | 868459108 | $48.2M | 2.49% | 1,036,328 | SH |
| 12 | Rhythm Pharmaceuticals Inc | RYTM | 76243J105 | $45.3M | 2.34% | 408,027 | SH |
| 13 | Gilead Sciences Inc | GILD | 375558103 | $43.3M | 2.24% | 343,100 | SH |
| 14 | United Therapeutics Corp Del | UTHR | 91307C102 | $41.4M | 2.14% | 76,489 | SH |
| 15 | Cogent Biosciences Inc | COGT | 19240Q201 | $40.1M | 2.07% | 1,035,148 | SH |
| 16 | Axsome Therapeutics Inc. | AXSM | 05464T104 | $39.3M | 2.03% | 160,429 | SH |
| 17 | Immatics N.V | IMTX | N44445109 | $37.2M | 1.92% | 3,669,346 | SH |
| 18 | Dyne Therapeutics Inc | DYN | 26818M108 | $36.8M | 1.90% | 1,658,384 | SH |
| 19 | Immunome Inc | IMNM | 45257U108 | $36.5M | 1.88% | 1,720,316 | SH |
| 20 | IDEAYA Biosciences Inc | IDYA | 45166A102 | $34.5M | 1.78% | 925,119 | SH |
| 21 | Anaptysbio Inc | ANAB | 032724106 | $33.3M | 1.72% | 493,536 | SH |
| 22 | Nektar Therapeutics | NKTR | 640268306 | $32.9M | 1.70% | 471,763 | SH |
| 23 | Pharvaris N V | PHVS | N69605108 | $30.5M | 1.58% | 881,299 | SH |
| 24 | Arcus Biosciences Inc | RCUS | 03969F109 | $29.2M | 1.51% | 945,690 | SH |
| 25 | Inhibrx Biosciences Inc | INBX | 45720N103 | $28.7M | 1.48% | 303,103 | SH |
| 26 | BioMarin Pharmaceutical Inc | BMRN | 09061G101 | $20.5M | 1.06% | 358,568 | SH |
| 27 | Veradermics Inc | MANE | 922967104 | $18.3M | 0.95% | 148,993 | SH |
| 28 | Alcon AG | ALC | H01301128 | $17.2M | 0.89% | 255,824 | SH |
| 29 | Insmed Inc | INSM | 457669307 | $16.9M | 0.87% | 158,398 | SH |
| 30 | Ultragenyx Pharmaceutical In Call | RARE | 90400D108 | $16.7M | 0.86% | 500,000 | SH |
| 31 | Intuitive Surgical Inc Call | ISRG | 46120E602 | $15.9M | 0.82% | 40,000 | SH |
| 32 | Globus Med Inc Call | GMED | 379577208 | $15.8M | 0.82% | 200,000 | SH |
| 33 | Edgewise Therapeutics Inc | EWTX | 28036F105 | $15.5M | 0.80% | 380,923 | SH |
| 34 | Exelixis Inc Put | EXEL | 30161Q104 | $13.8M | 0.72% | 254,200 | SH |
| 35 | Nurix Therapeutics Inc | NRIX | 67080M103 | $12.7M | 0.66% | 524,098 | SH |
| 36 | Design Therapeutics Inc | DSGN | 25056L103 | $12.5M | 0.65% | 865,135 | SH |
| 37 | Definium Therapeutics Inc | DFTX | 24477V105 | $12.0M | 0.62% | 255,903 | SH |
| 38 | First Tracks Biotherapeutics | TRAX | 337185102 | $11.4M | 0.59% | 565,199 | SH |
| 39 | Abbott Laboratories | ABT | 002824100 | $11.2M | 0.58% | 122,998 | SH |
| 40 | Disc Medicine Inc | IRON | 254604101 | $10.7M | 0.55% | 146,239 | SH |
| 41 | Tenax Therapeutics Inc | TENX | 88032L605 | $7.3M | 0.38% | 500,039 | SH |
| 42 | Sionna Therapeutics Inc | SION | 829401108 | $6.4M | 0.33% | 144,432 | SH |
| 43 | Absci Corporation | ABSI | 00091E109 | $3.9M | 0.20% | 337,400 | SH |
| 44 | Mirum Pharmaceuticals Inc | MIRM | 604749101 | $3.2M | 0.17% | 27,591 | SH |
| 45 | Jade Biosciences Inc | JBIO | 008064206 | $2.4M | 0.12% | 107,391 | SH |
| 46 | Savara Inc | SVRA | 805111101 | $2.2M | 0.12% | 364,763 | SH |
| 47 | Praxis Precision Medicines I | PRAX | 74006W207 | $2.2M | 0.11% | 6,440 | SH |
| 48 | Septerna Inc | SEPN | 81734D104 | $1.6M | 0.08% | 47,506 | SH |
| 49 | Onkure Therapeutics Inc | OKUR | 68277Q105 | $1.5M | 0.08% | 321,692 | SH |
| 50 | Sagimet Biosciences Inc | SGMT | 786700104 | $1.3M | 0.07% | 166,667 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $1.93B | 57 | 0001104659-26-096982 |
| 2026-03-31 | 2026-05-15 | $2.63B | 75 | 0001104659-26-062256 |
| 2025-12-31 | 2026-02-13 | $2.32B | 60 | 0001104659-26-015127 |
| 2025-09-30 | 2025-11-14 | $1.83B | 62 | 0001104659-25-111551 |
BUILDING 3-SUITE 150
Menlo Park, CA 94025